



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2003

---

## **Function of K<sup>+</sup> Channels in the Intestinal Epithelium**

Warth, R ; Barhanin, J

DOI: <https://doi.org/10.1007/s00232-002-2001-9>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-156251>

Journal Article

Published Version

Originally published at:

Warth, R; Barhanin, J (2003). Function of K<sup>+</sup> Channels in the Intestinal Epithelium. *Journal of Membrane Biology*, 193(2):67-78.

DOI: <https://doi.org/10.1007/s00232-002-2001-9>

## Topical Review

### Function of $K^+$ Channels in the Intestinal Epithelium

R. Warth<sup>1</sup>, J. Barhanin<sup>2</sup>

<sup>1</sup>Physiologisches Institut, Winterthurerstr. 190, 8057 Zürich, Switzerland

<sup>2</sup>Institut de Pharmacologie du CNRS, 660 route de Lucioles, 06560 Valbonne Sophia-Antipolis, France

Received: 11 September 2002

#### Introduction

Potassium channels play an important role for reabsorptive and secretory pathways in the gastro-intestinal tract. Over the last years molecular identification and functional characterization of  $K^+$  channels led to a better understanding of physiology and disease of intestinal transport. In gastric parietal cells KCNJ10 (Kir4.1) and heteromeric KCNE2/KCNQ1 (MiRP1/KvLQT1),  $K^+$  channels co-localize with the acid-producing  $H^+/K^+$  ATPase in the luminal membrane compartment. Specific  $K^+$  channel blockage and genetical disruption of the KCNQ1 gene in mice inhibit acid secretion almost completely. In small intestine,  $K^+$  channels provide the driving force for electrogenic reabsorption of nutrients in villus cells and secretion in intestinal crypt cells and they play an important role during cell volume regulation. In the colon, luminal  $K^+$  channels repolarize the membrane and support electrogenic  $Na^+$  reabsorption. In addition, they influence the final ionic composition of the feces.  $Ca^{2+}$ -regulated KCNN4  $K^+$  channels and KCNE3/KCNQ1 (MiRP2/KvLQT1)  $K^+$  channels are localized in the basolateral membrane of crypt cells in small and large intestine. The KCNE3/KCNQ1 channel complex is activated by cAMP during secretory diarrhea, i.e., via cholera toxin. Tissue-specific modulation of intestinal  $K^+$  channels could offer new therapeutic perspectives for the treatment of life-threatening forms of diarrhea or peptic ulcer disease.

#### Multifaceted Functions of $K^+$ Channels

Potassium channels are expressed in practically all mammalian cells. They are membrane proteins with

two, four or six transmembrane domains and have in common a pore-forming loop that is part of the  $K^+$ -selective filter [22]. Additional regulatory subunits and hetero-multimerization are important for membrane targeting, pharmacology, and functional properties [1, 2, 5, 103, 114, 116, 140]. Very recently, fascinating structural data shed light on the molecular principles of  $K^+$  channel structure and function [58, 59]. Helpful overviews on the molecular diversity and nomenclature of the about 85 different  $K^+$  channel genes are available online at <http://www.gene.ucl.ac.uk/nomenclature/gene-family/KCN.shtml> and at <http://www.ipmc.cnrs.fr/~duprat/>.


This review focuses on the physiological and pathophysiological role of  $K^+$  channels in epithelial cells of the gastro-intestinal tract. In intestinal epithelia  $K^+$  channels are involved in different cellular function.

#### HYPERPOLARIZATION AND GENERATION OF DRIVING FORCE FOR ELECTROGENIC TRANSPORT

Opening of basolateral  $K^+$  channels leads to a shift of the membrane voltage towards the Nernst potential for  $K^+$ , which at the basolateral side is in the range of  $-90$  mV.  $K^+$  is then recycled by the  $Na^+/K^+$  ATPase. The hyperpolarization increases the driving force for electrogenic transport: Since the paracellular pathway of the intestinal epithelium is relatively leaky and does not completely isolate the luminal from the basolateral side, a paracellular short-circuit current ( $I_{sc}$ ) is induced by the transepithelial voltage difference ( $V_{te}$ ) [36]. Thus, the basolateral  $K^+$  channel-induced hyperpolarization is conducted to the luminal membrane and hyperpolarizes this membrane. By this mechanism, opening of basolateral  $K^+$  channels supports basolateral and luminal electrogenic transport (Fig. 1) [41, 75]. Besides  $V_{te}$ , the paracellular ion flux depends on the specific ionic permeability of the paracellular barrier, which differs along the intestinal

Correspondence to: R. Warth; email: warthri@physiol.unizh.ch

**Key words:** Intestine — Transport — Potassium — Reabsorption — Secretion



**Fig. 1.** Role of K<sup>+</sup> channels during electrogenic transport. (A) A simplified circuit model for an epithelial cell layer (modified from [40, 41]). For simplification, Na<sup>+</sup>/K<sup>+</sup> ATPase pump current and paracellular diffusion potential have been omitted. Abbreviations:  $V_{te}$ , transepithelial voltage;  $V_a$ , apical membrane voltage;  $V_{bl}$ , basolateral membrane voltage;  $I_{sc}$ , short circuit current over the paracellular resistance;  $R_a$  apical membrane resistance;  $R_{bl}$ , basolateral membrane resistance;  $R_s$ , paracellular shunt resistance;  $E_a$ , electrochemical driving force of the apical membrane;  $E_{bl}$ , electrochemical driving force of the basolateral membrane. (B) In a theoretic epithelium having only luminal Cl<sup>-</sup>, basolateral K<sup>+</sup> channels, and no paracellular conductance,  $I_{sc}$  equals 0.  $V_a$  and  $V_{bl}$  are determined by the Nernst equilibrium for Cl<sup>-</sup> and K<sup>+</sup>, respectively. Neither Cl<sup>-</sup> nor K<sup>+</sup> leaves the cell because the driving force is missing. Despite a high

$V_{te}$  no transepithelial ion flux can occur. (C) Addition of a paracellular Na<sup>+</sup> permeability to model B leads to Na<sup>+</sup> flux to the lumen driven by  $V_{te}$ . This  $I_{sc}$  attenuates  $V_{te}$ , hyperpolarizes the luminal and depolarizes the basolateral membrane, resulting in Cl<sup>-</sup> and K<sup>+</sup> exit to the luminal and basolateral side, respectively. The epithelium secretes NaCl. (D) Additional activation of a luminal K<sup>+</sup> conductance ensues in electroneutral transcellular KCl secretion and further reduces  $V_{te}$ , thereby diminishing paracellular Na<sup>+</sup> flux. For a reabsorptive epithelium the luminal Cl<sup>-</sup> conductance in models C and D has to be replaced by electrogenic transport systems such as Na<sup>+</sup>-dependent glucose or amino-acid transport. In such an epithelium, a Cl<sup>-</sup>-selective paracellular conductance would cause paracellular Cl<sup>-</sup> reabsorption, resulting in transepithelial reabsorption of substrates, Na<sup>+</sup>, and Cl<sup>-</sup>. Water follows along the osmotic gradient.

tract, depending on the composition of barrier-forming proteins [23, 105].

#### $K^+$ SECRETION AND FINE-TUNING OF SALT METABOLISM

Luminal  $K^+$  channels directly hyperpolarize the apical membrane and lead to  $K^+$  secretion into the lumen. In contrast to basolateral  $K^+$  channels, activation of luminal  $K^+$  channels decreases  $V_{te}$ , thereby reducing the driving force for paracellular transport of ions. Luminal  $K^+$  channel activity in distal colon and distal renal nephron segments plays an important role for  $K^+$  excretion and  $Na^+$  reabsorption [3, 76]. These segments determine the final ion composition of feces and urine and are mainly regulated by the mineralocorticoid aldosterone and  $K^+$  intake.

#### RECYCLING OF $K^+$ ACROSS THE LUMINAL MEMBRANE

In gastric parietal cells and to less extent in colonic surface cells, luminal  $K^+$  channels are required to recycle  $K^+$  that has been taken up by  $H^+/K^+$  ATPases [37, 137]. In gastric glands, inhibition of the  $K^+$ -recycling channel blocks  $H^+/K^+$  ATPase activity and hence gastric acid secretion almost completely [38].

#### CELL VOLUME REGULATION

Transport of osmolytes and osmotic gradients across the luminal membrane represent a continuous challenge for volume regulation in intestinal cells. Upon hypotonic swelling, activation of  $K^+$  channels allows reduction of the concentration of intracellular osmolytes, thereby performing regulatory volume decrease [121]. In contrast, cell shrinkage leads to inhibition of  $K^+$  channels. Thus, volume regulation-induced changes of  $K^+$  channel activity can directly affect transepithelial ion transport [109, 137]. Several cloned  $K^+$  channels that are expressed in intestinal epithelium are affected by changes in cell volume (i.e., KCNN4 [44, 137], KCNK5 [96], and KCNQ1 [73]). An excellent review on cell volume regulating mechanisms is given in [68].

#### PROLIFERATION AND DIFFERENTIATION


$K^+$  channel activity is dependent on cell cycle, proliferation and differentiation. There is some evidence that  $K^+$  channels might be directly involved in the regulation of these processes [100, 141] and that pharmacological modulation of  $K^+$  channels can change cellular fate [60]. Recently, activation of  $K^+$  channels was observed in intestinal epithelial cells after wounding, which probably plays an important role for epithelial cell migration [107, 131]. During

cancer genesis in colonic epithelium, changes in ion channel expression have been observed [12]. It is of great interest to gain more insight into the mechanisms regulating the rapid cell renewal in the gastrointestinal tract. However, at present it is not clear whether the changes in ionic conductances are mainly secondary effects or whether the ionic properties interfere with the cellular fate in a more direct way.

Although all of the above mentioned different functions of  $K^+$  channels are of importance, we will focus in this review on the major task of the gastrointestinal epithelium: transport of substrates, salt and water.

#### Luminal $K^+$ Channels Are Required for Acid Secretion in Gastric Parietal Cells

In stomach mucosa, acid secretion occurs in a specialized cell type, the parietal cell. These mitochondria-rich cells have a unique morphology with invaginations of the luminal membrane into the cytoplasm and complex vesicular structures, so-called tubulocisternae, which amalgamate with the luminal membrane upon secretory stimuli [31]. The acid-producing enzyme  $H^+/K^+$ -ATPase is localized in these tubulocisternae. After amalgamation with the luminal membrane, the  $H^+/K^+$ -ATPase pumps  $H^+$  out of the cell, paralleled by an uptake of  $K^+$ .  $Cl^-$  is secreted into the lumen via apical  $ClC-2$   $Cl^-$  channels [82, 123]. To avoid  $K^+$  depletion of the luminal fluid due to  $H^+/K^+$  ATPase activity, a recycling pathway for  $K^+$  is required (Fig. 2A). There is good experimental evidence that  $K^+$  channels are the respective pathway [46, 138, 139]. In immunofluorescence experiments the KCNQ1  $K^+$  channel (formerly named KvLQT1) showed an  $H^+/K^+$ -ATPase-like distribution pattern in human parietal cells (Fig. 2B) [24, 38]. Its pharmacological inhibition by the chromanol 293B abolished acid secretion almost completely in vitro and in vivo. Most likely, KCNQ1 is associated with its regulatory subunit KCNE2 (MiRP1) to form the native channel complex [24, 38]. The functional role of KCNQ1 for acid secretion was underlined by observations in KCNQ1 knockout mice, which have an impaired acid secretion leading to hypergastrinemia and glandular gastric hypertrophy [69]. At present, it is not known whether homozygous KCNQ1 mutations in patients suffering from so-called Jervell-Lange-Nielsen syndrome [95] also lead to defects in gastric acid secretion. Very recently, another  $K^+$  channel was described in parietal cells: Immunofluorescence experiments and electron microscopy revealed a localization of KCNJ10 (Kir4.1) in the  $H^+/K^+$ -ATPase-containing membrane compartment, suggesting that besides KCNQ1 also KCNJ10 might play a role during acid secretion [37]. To date no data are available concerning the gastric



**Fig. 2.**  $K^+$  recycling is required for acid secretion in parietal cells. (A) Functional and morphological changes of a parietal cell during stimulation of acid secretion. In the absence of secretory stimuli  $H^+/K^+$  ATPase is located in intracellular vesicular structures (so-called tubulocisternae [31]). At present, it is not known whether  $K^+$  channels, required for  $K^+$  recycling, are located in  $H^+/K^+$  ATPase-containing vesicles or in separate vesicular structures. A connection of the tubulocisternae to the lumen does not yet exist. Upon stimulation via cAMP and  $IP_3/Ca^{2+}$  pathways, tubulocisternae get fused with the luminal membrane, thereby enlarging the luminal

surface and targeting  $H^+/K^+$ -ATPases and  $K^+$  channels to the apical side. Now  $K^+$  channels get activated by increasing concentrations of cAMP and cytosolic  $Ca^{2+}$ , and allow  $K^+$  recycling, which is necessary for ongoing  $H^+/K^+$ -ATPase activity. (B) Immunofluorescence of a resting human parietal cell with labeling of  $H^+/K^+$ -ATPases (left) and KCNQ1  $K^+$  channels (right). Both show a granular distribution pattern within the cell, suggesting a localization of the proteins in vesicles and tubulocisternae, which belong to the luminal membrane compartment.


phenotype of KCNJ10 knockout mice [85]. Further studies are required to elucidate nature, function and membrane targeting of luminal  $K^+$  channels during gastric acid secretion.

In the basolateral membrane the  $Cl^-/HCO_3^-$  exchanger serves  $Cl^-$  uptake and  $HCO_3^-$  extrusion. Basolateral  $Na^+/H^+$  exchangers stabilize intracellular pH and cell volume [110, 118]. With the patch-clamp technique,  $K^+$  conductances have been observed in the basolateral membrane and in whole-cell experiments [25, 90]; in whole-cell experiments [63], however, it is at present not clear whether they

provide the driving force for voltage-dependent basolateral transport or for luminal  $Cl^-$  exit. For the latter function paracellular permeability would be required (see Fig. 1), which has been shown to be rather low [36].

#### Function of $K^+$ Channels for Reabsorption and Secretion in Small Intestine

In small intestine most of the nutrients are digested and consecutively absorbed. The largest part of the




**Fig. 3.** Electrogenic transport in small intestine. (A) The mucosa of small intestine consists of crypt and villus cells. Reabsorption takes mainly place at the brushborder membrane of villus enterocytes. Goblet cells produce mucus, crypt cells secrete  $HCO_3^-$ -rich fluid to neutralize gastric acid. Stem cells for the rapid regeneration of enterocytes are localized at the crypt basis. (B) In the luminal membrane of villus cells, glucose and amino acids are reabsorbed in a secondary active way together with  $Na^+$ . This depolarizes the luminal membrane, leading to the generation of a lumen-negative transepithelial voltage ( $V_{te}$ ), which can drive reabsorption of anions via the paracellular pathway. Luminal  $K^+$  channels could play a role for repolarization [134]. There is also some evidence for an  $H^+/K^+$  exchange mechanism, probably via  $H^+/K^+$  ATPase [9]. The molecular identity of luminal and basolateral  $K^+$  channels is not known. The intermediate-conductance  $K^+$  channel is probably less expressed in the basolateral membrane of villus cells when com-

pared with crypt cells [47].  $ClC-2$   $Cl^-$  channels seem to mediate paracellular  $Cl^-$  fluxes [45] driven by the electro-chemical gradient. (C) Secretion in crypt cells requires activation of luminal  $Cl^-$  channels (CFTR), basolateral (and luminal)  $K^+$  channels, NKCC1 and  $Na^+/K^+$  ATPase [42, 125]. Heteromultimeric KCNE3/KCNQ1 channels represent a cAMP-activated  $K^+$  conductance. Their inhibition largely attenuates electrogenic  $Cl^-/HCO_3^-$  secretion. The intermediate-conductance  $K^+$  channel (probably KCNN4) is activated via increases in cytosolic  $Ca^{2+}$ .  $HCO_3^-$  leaves the cell via CFTR and via luminal anion exchangers (probably DRA). On the basolateral side,  $Cl^-$  can be taken up by NKCC1 and by  $Na^+$ -dependent and -independent anion exchangers (AE2 and NBC) [130]. Luminal  $Cl^-$  and basolateral  $K^+$  conductance create a lumen-negative  $V_{te}$ , that possibly induces paracellular  $Na^+$  fluxes. The mechanisms for  $HCO_3^-$  secretion are probably present in villus cells, too (B).

fluid is reabsorbed by the small intestinal mucosa and only some 20% enter the colon. The mass transport in the small intestine involves both transcellular and paracellular transport of solutes, ions and water. In order to fulfill different physiological demands, the reabsorptive capacity of small intestinal mucosa is regulated by transcriptional and non-transcriptional mechanisms. Thus, expression of transporters and ion channels can vary over a broad range, depending on the needs [53, 64, 97, 99].

Among the transcellular mechanisms, secondary active transport allows absorption of substrates even against a concentration gradient, i.e., by  $Na^+$ -coupled transporters for glucose and amino acids. Many of the transporters use the chemical gradient for  $Na^+$  or  $H^+$  and the negative membrane voltage as driving forces [86, 98]. The entry of a positive net charge via these systems depolarizes the luminal membrane of enterocytes, leading to a transepithelial voltage dif-

ference ( $V_{te}$ , see Fig. 1 and Fig. 3) and consecutively to paracellular electrogenic transport, i.e., transport of  $Cl^-$  [8, 45]. However, the depolarization of the luminal membrane reduces further voltage-dependent transcellular transport. To restore the transport capacity of the enterocytes,  $K^+$  channels are required to repolarize the membrane voltage. They can be localized in either the luminal or the basolateral membrane of villus cells (Fig. 3). It has been shown that activation of basolateral  $K^+$  channels by pinacidil or BRL 38227 increases  $NaCl$  reabsorption, paralleled by an enhanced short-circuit current [51]. Strong activation of luminal  $K^+$  channels, e.g., by cell swelling [80], could even produce a lumen-positive transepithelial voltage, which in turn would invert the direction of paracellular ion fluxes [45]. In another study, a nitric oxide-activated basolateral  $K^+$  conductance was described, whose activation by the  $K^+$  channel opener cromakalim enhanced net fluid reabsorption



**Fig. 4.** KCNE3/KCNQ1 K<sup>+</sup> channels in mouse jejunum. (A) Immunolocalization of KCNQ1 in mouse jejunum (overlay with differential interference contrast image). The KCNQ1-specific antibody [134] preferentially labeled the basolateral membrane of jejunal crypts cells. (B) Effect of the chromanol 293B on cAMP-activated secretion in mouse jejunum. Forskolin at 5 μM (FSK)

increased transepithelial voltage ( $V_{te}$ ) mainly by activation of luminal Cl<sup>-</sup> and basolateral KCNE3/KCNQ1 K<sup>+</sup> channels. 293B reduced  $V_{te}$  concentration-dependently by some 70%. Carbochol 100 μM (CCH) led to a rise in  $V_{te}$  by transiently activating Ca<sup>2+</sup>-activated K<sup>+</sup> channels (probably KCNN4).  $\Delta V_{te}$  is a measure for transepithelial resistance.


[115], indicating that luminal and basolateral K<sup>+</sup> conductances support reabsorption in small intestinal villus cells.

In the crypts of the small intestine, net secretion of bicarbonate, mucus, salt and water occurs, which allows buffering of acidic gastric content and facilitates propulsion of the intestinal content. Under pathological conditions, overwhelming activation of secretion, i.e., by cholera toxin, can lead to severe diarrhea. Transcellular transport in crypt cells is mainly a serosal-mucosal flux of Cl<sup>-</sup>, HCO<sub>3</sub><sup>-</sup> and K<sup>+</sup> [130], which is activated via cAMP and Ca<sup>2+</sup> pathways and to some extent via nitric oxide/cGMP [6]. Bicarbonate secretion plays an important role for mucosal protection and neutralization of gastric acid. However, the luminal pathway for bicarbonate exit is controversially discussed: It probably involves electrogenic systems such as CFTR channels (cystic fibrosis transmembrane conductance regulator) [21] and electroneutral Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchangers such as DRA (down-regulated in adenoma) [50, 55, 93, 104]. The amount of HCO<sub>3</sub><sup>-</sup> secreted via electrogenic transport systems is dependent on the membrane voltage and, thus, on K<sup>+</sup> channel activity. For the maintenance of electro-neutrality, Na<sup>+</sup> enters the lumen via the paracellular pathway driven by the

transepithelial voltage, and K<sup>+</sup> can be secreted via luminal K<sup>+</sup> channels (Fig. 3C).

Transcellular mass transport of nutrients, salt, and water is a continuous challenge for cellular volume regulation of enterocytes in small intestine. There is good evidence that K<sup>+</sup> channels play a role during regulatory volume decrease after swelling of villus enterocytes [79]. Moreover, it has been shown that Na<sup>+</sup>-dependent absorption of amino acids in enterocytes leads to activation of Na<sup>+</sup>/K<sup>+</sup> ATPase and of basolateral K<sup>+</sup> channels. The increase in basolateral K<sup>+</sup> conductance prevents rises in intracellular K<sup>+</sup> concentration (due to enhanced Na<sup>+</sup>/K<sup>+</sup> ATPase activity) and counteracts the depolarization caused by luminal electrogenic transport activity [39].

Compared with colonic K<sup>+</sup> channels, relatively little is known about the functional properties and the molecular identity of K<sup>+</sup> channels in the small intestine (Fig. 3) [124]. With electrophysiological methods several basolateral K<sup>+</sup> channels could be distinguished: an abundant large conductance "maxi" K<sup>+</sup> channel (90 to 250 pS) [15, 92, 122], an intermediate-conductance, Ca<sup>2+</sup>-activated K<sup>+</sup> channel, small-conductance channels [15], K<sub>ATP</sub>-like channels [30] and a chromanol 293B-sensitive K<sup>+</sup> conductance [134]. The regulation of the large-con-



**Fig. 5.** Role of  $K^+$  channels for secretion and absorption in distal colonic mucosa. (A) Colonic crypts consist of enterocytes, entero-endocrine cells and goblet cells. Absorption of short-chain fatty acids, salt, and water takes place in surface cells and the upper part of the crypt. At the crypt base, secretion and mitosis take place. (B) In surface cells  $Na^+$  enters the cell via ENaC and is exported via basolateral  $Na^+/K^+$  ATPase. CFTR  $Cl^-$  channels are less abundant than in crypt base cells. Without luminal  $K^+$  channel activity, ENaC-induced luminal depolarization leads to  $Cl^-$  reabsorption via CFTR. Activation of luminal  $K^+$  channels results in  $K^+$  secretion paralleled by luminal hyperpolarization. If the luminal membrane voltage is more negative than the  $Cl^-$  equilibrium potential, the direction of the CFTR  $Cl^-$  flux would invert: the cell

secretes KCl and reabsorbs  $Na^+$ . Luminal  $H^+/K^+$  ATPase serves mainly  $K^+$  reabsorption. Basolateral  $K^+$  channels provide a part of the driving force for luminal ion movement. (B) In crypt base cells, secretion requires cAMP-dependent activation of luminal CFTR  $Cl^-$  channels and of basolateral KCNE3/KCNQ1  $K^+$  channels.  $Ca^{2+}$  leads to activation of basolateral KCNN4  $K^+$  channels but requires a certain level of luminal CFTR activity to induce  $Cl^-$  secretion, because CFTR seems not to be directly  $Ca^{2+}$ -activated.  $Ca^{2+}$ -activated  $Cl^-$  channels play a minor role in normal tissue but can be observed during tumor genesis in colonic mucosa [12]. Driven by the transepithelial voltage,  $Na^+$  follows via the paracellular pathway.

ductance  $K^+$  channel by cAMP and  $Ca^{2+}$  is controversially discussed [15, 87, 92, 122]. The intermediate-conductance  $K^+$  channel is strongly activated by rises in cytosolic  $Ca^{2+}$  and by 1-ethyl-2-benzimidazolinone (1-EBIO) and shows functional characteristics similar to cloned IK1 channels (KCNN4) [47], suggesting that KCNN4 is the intermediate-conductance  $K^+$  channel as found in rat colonic crypts [135]. There is some evidence for a regulation of the intermediate-conductance  $K^+$  channel by cAMP [87], however, in another study no such regulation was observed [15]. Activation of this channel by 1-EBIO leads to a strong increase in  $Cl^-$  secretion but does not affect phloridzin-sensitive glucose absorption indicating that the 1-EBIO-activated  $K^+$  channel is mainly expressed in intestinal crypts and not or only little in villus cells [47].

The 293B-sensitive conductance is mainly located in crypt cells and formed by KCNQ1/KCNE3 channel proteins (Figs. 3C and 4A) [24, 134]. The KCNE3/KCNQ1 channel complex is activated during cAMP-stimulated secretion. Its inhibition blocks

electrogenic jejunal secretion by some 50–70% (Fig. 4B). Thus, KCNE3/KCNQ1 channels are a possible target for the treatment of life-threatening forms of secretory diarrhea, such as cholera. The 293B derivative IKs224 was shown to inhibit jejunal secretion with an  $IC_{50}$  in the nanomolar range [134]. However, clinical use of KCNE3/KCNQ1 blockers would require subunit specificity and/or locally restricted delivery of the drug, since one has to avoid inhibition of KCNE1/KCNQ1 channels in heart and inner ear.

### $K^+$ Channels in Colonic Mucosa

In contrast to mass transport in small intestine, the colonic mucosa serves the fine tuning of salt and water metabolism. Under physiological conditions absorption largely exceeds secretion: Some 90% of 1.5 l of intestinal content entering the colon are absorbed and only 150–200 g are excreted under physiological conditions. However, a certain level of secretion of mucins, electrolytes and water is



**Table 1.** Expression of K<sup>+</sup> channels in the gastrointestinal tract

Channel	HUGO symbol	Aliases	Stomach	Small intestine	Colon	Method/References
Large-conductance Ca <sup>2+</sup> -activated K <sup>+</sup> channels	KCNMA1 <sup>1</sup>	<b>KCa1, 1, SLO</b>	h +, rb + + +	h +	h + +, rb + +	DB [7], N, P [91], [70]
	KCNMB1 <sup>2</sup>	hslo-beta	h + +	h + +	h + +	DB [7]
	KCNMB2 <sup>2</sup>				h(-)	DB [7]
	KCNMB3 <sup>2</sup>		h + +	h + +	h + +	DB [7]
	KCNMB4 <sup>2</sup>				h +	DB [7]
MinK-related proteins (co-assembly with KCNQ1)	KCNE1	<b>IsK, minK</b>	m +, h -	h(+)	m(+)	N [20], P [132]
	KCNE2	<b>MIRP1</b>	h + + +, m + + +	m -	m(+)	N, IS [24], P [38], P [132]
	KCNE3	<b>MIRP2</b>	h + + +, m + +	m + +	m + + +	N [24], P [38], [117]
Inward rectifier	KCNJ1	<b>Kir1, 1f, ROMK6</b>		r +	r +	P [62]
	KCNJ10	<b>Kir4.1</b>	r + +			P [37]
	KCNJ13	Kir7.1	h + + +, r + +	h + + +	h(+)	N [101], N [94], P [37]
	KCNJ15	Kir4.2	r + +			P [37]
2-p-Domain K <sup>+</sup> channels	KCNK1	TWIK1	h(+), m + +	h(+), m + +	h(+), m + +	P [71], QP [88], P [4, 108]
	KCNK2	TREK1	h + +	h +	h -	P [71, 72], QP [88]
	KCNK3	TASK1	m +	h(+), m +	h(+)	N [32], P [71], N [61]
	KCNK5	TASK2	h +	h +		QP [88]
	KCNK6	TWIK2	h + +, m + + +	h + +, m +	h + +, m + +	QP [88], N [19], P [112]
	KCNK7		h + + + +	h + + +		QP [88]
	KCNK10	TREK2	h(+)	h +	h +	P [72], QP [88]
	KCNK12	THIK2	r +			P [106]
	KCNK13	THIK1	r +			P [106]
	KCNA4	<b>SK4, IK1, Kca4</b>	h + + +, m + +	h +	h + + +, r + + +, m + +	DP [56], P [135], N [54], N [74], P [128]
Intermediate-conductance Ca <sup>2+</sup> -activated K <sup>+</sup> channel						
KCNQ K <sup>+</sup> channels	KCNQ1	<b>KvLQT1</b>	m + + +, h + + +	m +, h + +	m + +, r + + +, h +	N [24], P [66], P [38], N [20], P, IS [26]

<sup>1</sup> Expression perhaps restricted to smooth muscle cells.<sup>2</sup> Probably localized in neurons; h, human tissue; r, rat tissue; m, mouse tissue; rb, rabbit tissue; P, PCR; QP, Quantitative PCR; N, Northern blot; DB, RNA dot blot; IS, in situ hybridization; in bold letters: experimental evidence for function in native intestinal mucosa.

required for normal transport and composition of feces. Thus, defects in secretion, i.e., in cystic fibrosis, can lead to severe constipation. On the other hand, impairment of colonic reabsorption leads to diarrhea, affecting salt/water and acid/base metabolism [67].

In the proximal part,  $Na^+$  is mainly reabsorbed via  $Na^+/H^+$  exchangers and in distal colon, via  $Na^+$  channels (ENaC). Depending on the needs of metabolism and hormone concentrations,  $K^+$  can be net-secreted via channels or reabsorbed by a luminal  $H^+/K^+$ -ATPase (Fig. 5) [10, 34, 89, 120]. A detailed list of hormones and mediators regulating colonic transport is given in [133]. Moreover, bacterial degradation of undigested nutrients leads to generation of short-chain fatty acids and ammonia, which are taken up by cells located at the surface of colonic crypts [17, 18, 48].

$K^+$  channels play a role for secretory and reabsorptive pathways. In particular the activity of luminal  $K^+$  channels affects the  $K^+$  balance of the body and therefore is regulated via  $K^+$  intake and different hormones. In the presence of high potassium diet [16, 113] or high aldosterone concentrations [35, 43, 76, 81],  $K^+$  channels hyperpolarize the luminal membrane of crypt cells, leading to electro-neutral transcellular secretion of KCl instead of transcellular  $Cl^-$  exit and paracellular  $Na^+$  flux (Fig. 1D). In surface epithelial cells, the  $K^+$  channel-induced hyperpolarization increases the driving force for  $Na^+$  uptake via ENaC in distal colon. These  $K^+$  conductances are modulated by cholinergic and cAMP-mediated pathways [29, 49, 84, 119]. Direct functional characterization of luminal  $K^+$  channels with the patch-clamp technique is hampered by mucus and microvilli, which make measurements very difficult. There is evidence for large-conductance  $K^+$  channels with single-channel conductances from 120–230 pS [16, 113, 133] and for a pH-sensitive ROMK-type channel [52, 62, 133]. Data from KCNMA1 knockout mice indicate that maxi  $K^+$  channels play a role in  $K^+$  secretion after purinergic receptor stimulation [70]. The inhibitory effect of the chromanol 293B on cAMP-activated serosal-to-mucosal  $Rb^+$  flux suggests that KCNQ1 might be localized in luminal and basolateral membranes [29]. In the luminal membrane, KCNQ1 could co-assemble with the small regulatory proteins KCNE1 or KCNE2 [132].

In the basolateral membrane of colonic mucosa at least three different types of  $K^+$  channels are present: (1) a large-conductance  $K^+$  channel that is very abundant in rabbit colon [77, 78, 127]; (2) KCNN4 underlying the intermediate-conductance  $Ca^{2+}$ -activated  $K^+$  channel [14, 27, 135], and (3) KCNQ1, a very small-conductance  $K^+$  channel that is stimulated via cAMP and blocked by 293B [11, 24, 26, 65, 75, 117, 136].

Upon cholinergic stimulation of rat colonic mucosa, a strong but transient opening of KCNN4 channels is observed, leading to hyperpolarization of the basolateral membrane. The basolateral hyperpolarization increases the transepithelial potential difference if the luminal membrane is depolarized by  $Cl^-$  channels [13, 49]. Interestingly, the  $Ca^{2+}$  pathway alone seems not to activate sufficiently the luminal  $Cl^-$  conductance in normal colonic mucosa: in the absence of cAMP-mediated activation of luminal  $Cl^-$  channels, cholinergic stimulation by carbachol inverts the polarity of the  $V_{te}$  and leads to a lumen-positive transepithelial voltage via activation of luminal  $K^+$  channels [83]. However, during carcinogenesis,  $Ca^{2+}$ -activated  $Cl^-$  channels are expressed, counteracting the hyperpolarizing effect of KCNN4 channel opening [12] and thereby mimicking the effect of carbachol in some colonic cell lines. Colonic KCNN4 channels are potently blocked by the antifungal drug clotrimazole and activated by 1-EBIO [28, 102, 129, 135]. Pharmacological activation and inhibition of colonic KCNN4 channels have been discussed as strategies for the treatment of cystic fibrosis and diarrhea, respectively [28, 57, 111, 126]. Basolateral  $K^+$  channel inhibition was claimed to mediate the effect of the antidiarrheal drug loperamide [33].

In large intestine cAMP-mediated secretion plays an important role for normal transport of feces, which is impaired in cystic fibrosis. On the other hand, some bacterial toxins, such as cholera toxin, induce an overwhelming secretion in small and large intestine [133]. It has been shown that cAMP decreases intracellular  $Ca^{2+}$  activity of colonocytes via depolarization-induced reduction of  $Ca^{2+}$  influx. Thus, KCNN4-type  $Ca^{2+}$ -dependent  $K^+$  channels are closed during cAMP-mediated secretion [13]. Under these conditions, the driving force for luminal  $Cl^-$  exit mainly depends on cAMP-activated KCNQ1  $K^+$  channels. The KCNQ1 inhibition by 293B was shown to block the electrogenic part of  $Cl^-$  secretion (Fig. 1C) [75] and the minor electroneutral secretion of KCl (Fig. 1D) [29]. Like in small intestine, KCNQ1 is associated with its regulatory subunit KCNE3 in the basolateral membrane of colonic enterocytes. In contrast to the cardiac KCNE1/KCNQ1 channel complex, which is voltage-dependent and slowly activating, KCNE3/KCNQ1 channels are voltage-independent and constitutively open [117].

### More Intestinal $K^+$ Channels in the Future?

During the last years a number of new  $K^+$  channel transcripts, i.e., for several maxi  $K^+$  channels and 2-p-domain  $K^+$  channels, have been found in the gastrointestinal tract and the list of intestinal  $K^+$  channel genes (Table 1) is probably not complete.

On the other hand, for expression analysis, often commercially available samples of total tissue cDNA or RNA (including muscle layers and neuronal cells) were used. In these cases it is not proven that the respective K<sup>+</sup> channels are localized in the epithelial cells. Only for a very limited number of channels epithelial expression, cellular localization and a functional role in the native tissue could be shown. However, these data led to a better understanding of transport in the intestinal tract and these channels could be targets of drug development for the treatment of transport-related diseases.

Supported by a "Forschungskredit der Universität Zürich" to R.W.

## References

- Abbott, G.W., Sesti, F., Splawski, I., Buck, M.E., Lehmann, M.H., Timothy, K.W., Keating, M.T., Goldstein, S.A. 1999. *Cell* **97**:175–187
- Aguilar-Bryan, L., Nichols, C.G., Wechsler, S.W., Clement, J.P., Boyd, A.E., González, G., Herrera-Sosa, H., Nguy, K., Bryan, J., Nelson, D.A. 1995. *Science* **268**:423–426
- Arrighi, I., Bloch-Faure, M., Grahmmer, F., Bleich, M., Warth, R., Mengual, R., Drici, M.D., Barhanin, J., Meneton, P. 2001. *Proc. Natl. Acad. Sci. USA* **98**:8792–8797
- Arrighi, I., Lesage, F., Scimeca, J.C., Carle, G.F., Barhanin, J. 1998. *FEBS Lett.* **425**:310–316
- Barhanin, J., Lesage, F., Guillemare, E., Fink, M., Lazdunski, M., Romey, G. 1996. *Nature* **384**:78–80
- Barry, M.K., Aloisi, J.D., Yeo, C.J. 1995. *J. Surg. Res.* **59**:681–686
- Behrens, R., Nolting, A., Reimann, F., Schwarz, M., Waldschutz, R., Pongs, O. 2000. *FEBS Lett.* **474**:99–106
- Bijlsma, P.B., Bakker, R., Groot, J.A. 1997. *J. Membrane Biol.* **157**:127–137
- Binder, H.J., Murer, H. 1986. *J. Membrane Biol.* **91**:71–84
- Binder, H.J., Sangan, P., Rajendran, V.M. 1999. *Semin. Nephrol.* **19**:405–414
- Bleich, M., Briel, M., Busch, A.E., Lang, H.J., Gerlach, U., Gögelein, H., Greger, R., Kunzelmann, K. 1997. *Pfluegers Arch.* **34**:499–501
- Bleich, M., Ecker, D., Schwartz, B., Fraser, G., Greger, R. 1997. *Pfluegers Arch.* **433**:254–259
- Bleich, M., Riedemann, N., Warth, R., Kerstan, D., Leipziger, J., Hör, M., Van Driessche, W., Greger, R. 1996. *Pfluegers Arch.* **432**:1011–1022
- Burckhardt, B.-C., Gögelein, H. 1992. *Pfluegers Arch.* **420**:54–60
- Butt, A.G., Hamilton, K.L. 1998. *Pfluegers Arch.* **435**:528–538
- Butterfield, I., Warhurst, G., Jones, M.N., Sandle, G.I. 1997. *J. Physiol.* **501**:537–547
- Castell, D.O., Moore, E.W. 1971. *Gastroenterology* **60**:33–42
- Charney, A.N., Micic, L., Egnor, R.W. 1998. *Am. J. Physiol.* **274**:G518–24
- Chavez, R.A., Gray, A.T., Zhao, B.B., Kindler, C.H., Mazurek, M.J., Mehta, Y., Forsayeth, J.R., Yost, C.S. 1999. *J. Biol. Chem.* **274**:7887–7892
- Chouabe, C., Neyroud, N., Guicheney, P., Lazdunski, M., Romey, G., Barhanin, J. 1997. *EMBO J.* **16**:5472–5479
- Clarke, L.L., Stien, X., Walker, N.M. 2001. *J. Pancreas* **2**:263–267
- Coetzee, W.A., Amarillo, Y., Chiu, J., Chow, A., Lau, D., McCormack, T., Moreno, H., Nadal, M.S., Ozaita, A., Po-untney, D., Saganich, M., Vega-Saenz, d.M., Rudy, B. 1999. *Ann. N. Y. Acad. Sci.* **868**:233–285
- Colegio, O.R., Van Itallie, C.M., McCrea, H.J., Rahner, C., Anderson, J.M. 2002. *Am. J. Physiol.* **283**:C142–C147
- Dedek, K., Waldegger, S. 2001. *Pfluegers Arch.* **442**:896–902
- Demarest, J.R., Loo, D.D. 1990. *Annu. Rev. Physiol.* **52**:307–319
- Demolombe, S., Franco, D., de Boer, P., Kupersmidt, S., Roden, D., Pereon, Y., Jarry, A., Moorman, A.F., Escande, D. 2001. *Am. J. Physiol.* **280**:C359–C372
- Devor, D.C., Frizzell, R.A. 1998. *Am. J. Physiol.* **274**:C138–C148
- Devor, D.C., Singh, A.K., Frizzell, R.A., Bridges, R.J. 1996. *Am. J. Physiol.* **271**:L775–784
- Diener, M., Hug, F., Strabel, D., Scharrer, E. 1996. *Br. J. Pharmacol.* **118**:1477–1487
- Dubinsky, W.P., Mayorga-Wark, O., Schultz, S.G. 1998. *Am. J. Physiol.* **275**:C1653–C1659
- Duman, J.G., Pathak, N.J., Ladinsky, M.S., McDonald, K.L., Forte, J.G. 2002. *J. Cell Sci.* **115**:1251–1258
- Duprat, F., Lesage, F., Fink, M., Reyes, R., Heurteaux, C., Lazdunski, M. 1997. *EMBO* **16**:5464–5471
- Epple, H.J., Fromm, M., Riecken, E.O., Schulzke, J.D. 2001. *Scand. J. Gastroenterol.* **36**:731–737
- Foster, E.S., Budinger, M.E., Hayslett, J.P., Binder, H.J. 1986. *J. Clin. Invest.* **77**:228–235
- Fromm, M., Schulzke, J.D., Hegel, U. 1990. *Pfluegers Arch.* **416**:573–579
- Frömter, E., Diamond, J. 1972. *Nature* **235**:9–13
- Fujita, A., Horio, Y., Higashi, K., Mouri, T., Hata, F., Takeguchi, N., Kurachi, Y. 2002. *J. Physiol.* **540**:85–92
- Grahmmer, F., Herling, A.W., Lang, H.J., Schmitt-Gräff, A., Wittekindt, O.H., Nitschke, R., Bleich, M., Barhanin, J., Warm, R. 2001. *Gastroenterology* **120**:1363–1371
- Grasset, E., Gunter-Smith, P., Schultz, S.G., 1983. *J. Membrane Biol.* **71**:89–94
- Greger, R. 1996. Epithelial transport. In: Comprehensive Human Physiology. 1217–1232. R. Greger, U. Windhorst, ed., Springer, Berlin, Heidelberg, New York
- Greger, R., Schlatter, E. 1983. *Pfluegers Arch.* **396**:325–334
- Greger, R., Schlatter, E., Gögelein, H. 1986. *News Physiol. Sci.* **1**:134–136
- Grotjoharm, I., Gitter, A.H., Kockerling, A., Bertog, M., Schulzke, J.D., Fromm, M. 1998. *J. Physiol.* **507**:561–570
- Grunnet, M., MacAulay, N., Jorgensen, N.K., Jensen, S., Olesen, S.P., Klaerke, D.A. 2002. *Pfluegers Arch.* **444**:167–177
- Gyomai, K., Yeger, H., Ackerley, C., Garami, E., Bear, C.E. 2000. *Am. J. Physiol.* **279**:C1787–C1794
- Hagen, S.J., Wu, H., Morrison, S.W. 2000. *Am. J. Physiol.* **279**:G400–G410
- Hamilton, K.L., Meads, L., Butt, A.G. 1999. *Pfluegers Arch.* **439**:158–166
- Hasselblatt, P., Warth, R., Schulz-Baldes, A., Greger, R., Bleich, M. 2000. *Pfluegers Arch.* **441**:118–124
- Heinke, B., Hörger, S., Diener, M. 1998. *Eur. J. Pharmacol.* **362**:199–206
- Hoglund, P., Haila, S., Socha, J., Tomaszewski, L., Saarialho-Kere, U., Karjalainen-Lindsberg, M.L., Airola, K., Holmberg, C., de la Chapelle, A., Kere, J. 1996. *Nat. Genet.* **14**:316–319

51. Homaidan, F.R., Broutman, G. 1994. *Eur. J. Pharmacol.* **271**:561–565
52. Huang, Y., Wong, P.Y.D. 1996. *J. Cell. Physiol.* **168**:678–683
53. Ihara, T., Tsujikawa, T., Fujiyama, Y., Bamba, T. 2000. *Digestion* **61**:59–67
54. Ishii, T.M., Silvia, C., Hirschberg, B., Bond, C.T., Adelman, J.P., Maylie, J. 1997. *Proc. Natl. Acad. Sci. USA* **94**:11651–11656
55. Jacob, P., Rossmann, H., Lamprecht, G., Kretz, A., Neff, C., Lin-Wu, E., Gregor, M., Groneberg, D.A., Kere, J., Seidler, U. 2002. *Gastroenterology* **122**:709–724
56. Jensen, B.S., Strobaek, D., Christophersen, P., Jorgensen, T.D., Hansen, C., Silaharoglu, A., Olesen, S.P., Ahring, P.K. 1998. *Am. J. Physiol.* **275**:C848–C856
57. Jensen, B.S., Strobaek, D., Olesen, S.P., Christophersen, P. 2001. *Curr. Drug Targets* **2**:401–422
58. Jiang, Y., Lee, A., Chen, J., Cadene, M., Chait, B.T., MacKinnon, R. 2002. *Nature* **417**:515–522
59. Jiang, Y., Lee, A., Chen, J., Cadene, M., Chait, B.T., MacKinnon, R. 2002. *Nature* **417**:523–526
60. Khanna, R., Chang, M.C., Joiner, W.J., Kaczmarek, L.K., Schlichter, L.C. 1999. *J. Biol. Chem.* **274**:14838–14849
61. Kim, D., Fujita, A., Horio, Y., Kurachi, Y. 1998. *Circ. Res.* **82**:513–518
62. Kondo, C., Isomoto, S., Matsumoto, S., Yamada, M., Horio, Y., Yamashita, S., Takemura-Kameda, K., Matsuzawa, Y., Kurachi, Y. 1996. *FEBS Lett.* **399**:122–126
63. Kotera, T., Hashimoto, A., Ueda, S., Okada, Y. 1991. *J. Membrane Biol.* **124**:43–52
64. Koyama, K., Sasaki, I., Naito, H., Funayama, Y., Fukushima, K., Unno, M., Matsuno, S., Hayashi, H., Suzuki, Y. 1999. *Am. J. Physiol.* **276**:G975–G984
65. Kunzelmann, K., Bleich, M., Warm, R., Levy-Holzman, R., Garty, H., Schreiber, R. 2001. *Clin. Exp. Pharmacol. Physiol.* **28**:79–83
66. Kunzelmann, K., Hübner, M., Schreiber, R., Levy-Holzman, R., Garty, H., Bleich, M., Warth, R., Slavik, M., von Hahn, T., Greger, R. 2001. *J. Memb. Biol.* **119**:155–164
67. Kunzelmann, K., Mall, M. 2002. *Physiol. Rev.* **82**:245–289
68. Lang, F., Busch, G.L., Ritter, M., Volkl, H., Waldegger, S., Gulbins, E., Haussinger, D. 1998. *Physiol. Rev.* **18**:247–306
69. Lee, M.P., Ravenel, J.D., Hu, R.J., Lustig, L.R., Tomaselli, G., Berger, R.D., Brandenburg, S.A., Litzi, T.J., Bunton, T.E., Limb, C., Francis, H., Gorelikow, M., Gu, H., Washington, K., Argani, P., Goldenring, J.R., Coffey, R.J., Feinberg, A.P. 2000. *J. Clin. Invest.* **106**:1447–1455
70. Leipziger, J., Matos, J., Sausbier, M., Ruth, P. 2003. *Pfluegers Arch. in press*
71. Lesage, F., Lazdunski, M. 2000. *Am. J. Physiol.* **279**:F793–F801
72. Lesage, F., Terrenoire, C., Romey, G., Lazdunski, M. 2000. *J. Biol. Chem.* **275**:28398–28405
73. Lock, H., Valverde, M.A. 2000. *J. Biol. Chem.* **275**:34849–34852
74. Logsdon, N.J., Kang, J., Togo, J.A., Christian, E.P., Aiyar, J. 1997. *J. Biol. Chem.* **272**:32723–32726
75. Lohrmann, E., Burhoff, I., Nitschke, R.B., Lang, H.J., Mania, D., Englert, H.C., Hropot, M., Warth, R., Rohm, W., Bleich, M., Greger, R. 1995. *Pfluegers Arch.* **429**:517–530
76. Lomax, R.B., McNicholas, C.M., Lombes, M., Sandle, G.I. 1994. *Am. J. Physiol.* **266**:G71–G82
77. Lomax, R.B., Warhurst, G., Sandle, G.I. 1996. *Gut* **38**:243–247
78. Loo, D.D.F., Kaunitz, J.D. 1989. *J. Membrane Biol.* **110**:19–28
79. MacLeod, R.J., Hamilton, J.R. 1999. *J. Membrane Biol.* **172**:59–66
80. MacLeod, R.J., Hamilton, J.R. 1999. *J. Membrane Biol.* **172**:47–58
81. Maguire, D., MacNamara, B., Cuffe, J.E., Winter, D., Doolan, C.M., Urbach, V., O'Sullivan, G.C., Harvey, B.J. 1999. *Steroids* **64**:51–63
82. Malinowska, D.H., Kupert, E.Y., Bahinski, A., Sherry, A.M., Cuppoletti, J. 1995. *Am. J. Physiol.* **268**:C191–C200
83. Mall, M., Bleich, M., Schürlein, M., Kühr, J., Seydewitz, H.H., Brandis, M., Greger, R., Kunzelmann, K. 1998. *Am. J. Physiol.* **275**:G1274–G1281
84. Mall, M., Wissner, A., Seydewitz, H.H., Kuehr, J., Brandis, M., Greger, R., Kunzelmann, K. 2000. *Am. J. Physiol.* **278**:G617–G624
85. Marcus, D.C., Wu, T., Wangemann, P., Kofuji, P. 2002. *Am. J. Physiol.* **282**:C403–C407
86. Matthews, J.C., Anderson, K.J. 2002. *Curr. Opin. Clin. Nutr. Metab. Care* **5**:77–84
87. McNicholas, C.M., Fraser, G., Sandle, G.I. 1994. *J. Physiol.* **477**:381–392
88. Medhurst, A.D., Rennie, G., Chapman, C.G., Meadows, H., Duckworth, M.D., Kelsell, R.E., Gloger, I.I., Pangalos, M.N. 2001. *Brain Res. Mol. Brain Res.* **86**:101–114
89. Meneton, P., Schultheis, P.J., Greeb, J., Nieman, M.L., Liu, L.H., Clarke, L.L., Duffy, J.J., Doetschman, T., Lorenz, J.N., Shull, G.E. 1998. *J. Clin. Invest.* **101**:536–542
90. Mieno, H., Kajiyama, G. 1991. *Am. J. Physiol.* **261**:G206–G212
91. Morita, T., Hanaoka, K., Morales, M.M., Montrose-Rafizadeh, C., Guggino, W.B. 1997. *Am. J. Physiol.* **273**:F615–F624
92. Morris, A.P., Gallacher, D.V., Lee, J.A. 1986. *FEBS Lett.* **206**:87–92
93. Moseley, R.H., Höglund, P., Wu, G.D., Silberg, D.G., Haila, S., de la Chapelle, A., Holmberg, C., Kere, J. 1999. *Am. J. Physiol.* **276**:G185–G192
94. Nakamura, N., Suzuki, Y., Sakuta, H., Ookata, K., Kawahara, K., Hirose, S. 1999. *Biochem. J.* **342**:329–336
95. Neyroud, N., Tesson, F., Denjoy, I., Leibovici, M., Doncker, C., Barhanin, J., Faure, S., Gary, F., Coumel, P., Petit, C., Schwartz, K., Guicheney, P. 1997. *Nature Genet.* **15**:186–189
96. Niemeyer, M.I., Cid, L.P., Barros, L.F., Sepulveda, F.V. 2001. *J. Biol. Chem.*
97. Pacha, J. 2000. *Physiol. Rev.* **80**:1633–1667
98. Palacin, M., Estevez, R., Bertran, J., Zorzano, A. 1998. *Physiol. Rev.* **78**:969–1054
99. Pan, X., Terada, T., Irie, M., Saito, H., Inui, K. 2002. *Am. J. Physiol.* **283**:G57–G64
100. Pardo, L.A., del Camino, D., Sanchez, A., Alves, F., Bruggemann, A., Beckh, S., Stuhmer, W. 1999. *EMBO J.* **18**:5540–5547
101. Partiseti, M., Collura, V., Agnel, M., Culouscou, J.M., Graham, D. 1998. *FEBS Lett.* **434**:171–176
102. Pedersen, K.A., Schroder, R.L., Skaaning-Jensen, B., Strobaek, D., Olesen, S.-P., Christophersen, P. 1999. *Biochim. Biophys. Acta* **1420**:231–240
103. Pongs, O., Leicher, T., Berger, M., Roeper, J., Bähring, R., Wray, D., Giese, K.P., Silva, A.J., Storm, J.F. 1999. *Ann. N. Y. Acad. Sci.* **868**:344–355
104. Praetorius, J., Friis, U.G., Ainsworth, M.A., Schaffalitzky de Muckadell, O.B., Johansen, T. 2002. *Acta Physiol. Scand.* **174**:327–336
105. Rahner, C., Mitic, L.L., Anderson, J.M. 2001. *Gastroenterology* **120**:411–422

106. Rajan, S., Wischmeyer, E., Karschin, C., Preisig-Muller, R., Grzeschik, K.H., Daut, J., Karschin, A., Derst, C. 2000. *J. Biol. Chem.* **276**:7302–7311
107. Rao, J.N., Platoshyn, O., Li, L., Guo, X., Golovina, V.A., Yuan, J.X., Wang, J.Y. 2002. *Am. J. Physiol.* **282**:C885–C898
108. Reyes, R., Duprat, F., Lesage, F., Fink, M., Salinas, M., Farman, N., Lazdunski, M. 1998. *J. Biol. Chem.* **273**:30863–30869
109. Ribeiro, R., Heinke, B., Diener, M. 2001. *Acta Physiol. Scand.* **171**:445–458
110. Rossmann, H., Sonnentag, T., Heinzmann, A., Seidler, B., Bachmann, O., Vieillard-Baron, D., Gregor, M., Seidler, U. 2001. *Am. J. Physiol.* **281**:G447–G458
111. Rufo, P.A., Merlin, D., Riegler, M., Ferguson-Maltzman, M.H., Dickinson, B.L., Brugnara, C., Alper, S.L., Lencer, W.I. 1997. *J. Clin. Invest.* **100**:3111–3120
112. Salinas, M., Reyes, R., Lesage, F., Fosset, M., Heurteaux, C., Romey, G., Lazdunski, M. 1999. *J. Biol. Chem.* **274**:11751–11760
113. Sandle, G.I., Butterfield, I. 1999. *Gut* **44**:40–46
114. Sanguinetti, M.C., Curran, M.E., Zou, A., Shen, J., Spector, P.S., Atkinson, D.L., Keating, M.T. 1996. *Nature* **384**:80–83
115. Schirgi-Degen, A., Beubler, E. 1996. *Eur. J. Pharmacol.* **316**:257–262
116. Schroeder, B.C., Kubisch, C., Stein, V., Jentsch, T.J. 1998. *Nature* **396**:687–690
117. Schroeder, B.C., Waldegger, S., Fehr, S., Bleich, M., Warth, R., Greger, R., Jentsch, T.J. 2000. *Nature* **403**:196–199
118. Schultheis, P.J., Clarke, L.L., Meneton, P., Harline, M., Boivin, G.P., Stemmermann, G., Duffy, J.J., Doetschman, T., Miller, M.L., Shull, G.E. 1998. *J. Clin. Invest.* **101**:1243–1253
119. Schultheis, G., Diener, M. 1997. *Br. J. Pharmacol.* **122**:87–94
120. Schultz, S.G. 1984. *Annu. Rev. Physiol.* **46**:435–451
121. Schultz, S.G., Dubinsky, W.P. 2001. *J. Membrane Biol.* **184**:255–261
122. Sepulveda, F.V., Mason, W.T. 1985. *FEBS Lett.* **191**:87–91
123. Sherry, A.M., Malinowska, D.H., Morris, R.E., Ciruolo, G.M., Cuppoletti, J. 2001. *Am. J. Physiol.* **280**:C1599–C1606
124. Shieh, C.C., Coghlan, M., Sullivan, J.P., Gopalakrishnan, M. 2000. *Pharmacol. Rev.* **52**:557–594
125. Silva, P., Stoff, J., Field, M., Fine, L., Forrest, J.N., Epstein, F.H. 1977. *Am. J. Physiol.* **233**:F298–F306
126. Singh, S., Syme, C.A., Singh, A.K., Devor, D.C., Bridges, R.J. 2001. *J. Pharmacol. Exp. Ther.* **296**:600–611
127. Turnheim, K., Plass, H., Wyskovsky, W. 2002. *Biochim. Biophys. Acta* **1560**:51–66
128. Vandompe, D.H., Shmukler, B.E., Jiang, L., Lim, B., Maylie, J., Adelman, J.P., de Franceschi, L., Cappellini, M.D., Brugnara, C., Alper, S.L. 1998. *J. Biol. Chem.* **273**:21542–21553
129. von Hahn, T., Thiele, I., Zingaro, L., Hamm, K., Garcia Alzamora, M., Kottgen, M., Bleich, M., Warth, R. 2001. *Cell Physiol. Biochem.* **11**:219–230
130. Walker, N.M., Flagella, M., Gawenis, L.R., Shull, G.E., Clarke, L.L. 2002. *Gastroenterology* **123**:531–541
131. Wang, J.Y., Wang, J., Golovina, V.A., Li, L., Platoshyn, O., Yuan, J.X. 2000. *Am. J. Physiol.* **278**:C303–C314
132. Warth, R., Barhanin, J. 2002. *Am. J. Physiol.* **282**:R639–R648
133. Warth, R., Bleich, M. 2000. *Rev. Physiol. Biochem. Pharmacol.* **140**:1–62
134. Warth, R., Garcia, A.M., Kim, K., Zdebik, A., Nitschke, R., Bleich, M., Gerlach, U., Barhanin, J., Kim, J. 2002. *Pfluegers Arch.* **443**:822–828
135. Warth, R., Hamm, K., Bleich, M., Kunzelmann, K., von Hahn, T., Schreiber, R., Ullrich, E., Mengel, M., Trautmann, N., Kindle, P., Schwab, A., Greger, R. 1999. *Pfluegers Arch.* **438**:437–444
136. Warth, R., Riedemann, N., Bleich, M., Van Driessche, W., Busch, A.E., Greger, R. 1996. *Pfluegers Arch.* **432**:81–88
137. Weyand, B., Warth, R., Bleich, M., Greger, R. 1998. *Pfluegers Arch.* **436**:227–232
138. Wolosin, J.M., Forte, J.G. 1984. *Am. J. Physiol.* **246**:C537–C545
139. Wolosin, J.M., Forte, J.G. 1985. *J. Membrane Biol.* **83**:261–272
140. Xia, X.-M., Fakler, B., Rivard, A., Wayman, G., Johnson-Pais, T., Keen, J.E., Ishii, T., Hirschberg, B., Bond, C.T., Lutsenko, S., Maylie, J., Adelman, J.P. 1998. *Nature* **395**:503–507
141. Yao, X., Kwan, H.Y. 1999. *Life Sci.* **65**:55–62